Detalles de la búsqueda
1.
Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.
Diabetes Obes Metab
; 22(7): 1176-1186, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32128957
2.
Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes.
Diabetes Obes Metab
; 22(8): 1292-1301, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32175655
3.
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.
Diabetes Obes Metab
; 21(11): 2429-2439, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31264757
4.
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
Int J Cancer
; 143(12): 3240-3247, 2018 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29978467
5.
Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.
BMJ Open Diabetes Res Care
; 9(1)2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34172436
6.
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
Diabetes Care
; 42(9): 1733-1741, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31320446
Resultados
1 -
6
de 6
1
Próxima >
>>